<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar334</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Meeting abstract</dochead>
      <bibl>
         <title>
            <p>Adeno-associated virus preferentially transduces human compared to mouse synovium</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Jennings</snm>
               <fnm>K</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Katakura</snm>
               <fnm>S</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Burstein</snm>
               <fnm>H</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Gao</snm>
               <fnm>G</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Wilson</snm>
               <fnm>JM</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Hirsch</snm>
               <fnm>R</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Institute for Human Gene Therapy, University of Pennsylvania Health System, Philadelphia, PA 19104, USA; Targeted Genetics Corp, Seattle, WA 98101, USA</p>
            </ins>
         </insg>
         <source>Arthritis Res</source>
         <supplement>
            <title>
               <p>Innovative Rheumatology: Gene and Cell Therapies of Arthritis and Related Autoimmune Disorders. Second International Meeting</p>
            </title>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>Innovative Rheumatology: Gene and Cell Therapies of Arthritis and Related Autoimmune Disorders. Second International Meeting</p>
            </title>
            <location>Montpellier, France</location>
            <date-range>17&#8211;18 May 2001</date-range>
         </conference>
         <issn>1465-9905</issn>
         <pubdate>2001</pubdate>
         <volume>3</volume>
         <issue>Suppl 1</issue>
         <fpage>P1</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar334</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>6</day>
               <month>4</month>
               <year>2001</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>25</day>
               <month>4</month>
               <year>2001</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2001</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <meta>
      <classifications>
         <classification type="BMC" subtype="old_arx_id">ar-3-s1-p1</classification>
      </classifications>
   </meta>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>There is increasing interest in adeno-associated virus (AAV) vectors for a wide variety of gene therapy applications. AAV is a nonpathogenic human parvovirus that can mediate long-term transduction of a number of cell types without provoking a significant immune response. These properties make AAV especially attractive for use in gene therapy of rheumatoid arthritis (RA), a chronic inflammatory disease. To investigate the potential of AAV in gene therapy of arthritis, the ability of AAV to infect synovium <it>in vitro</it> and <it>in vivo</it> was tested. Three human RA synovial fibroblast cell lines and two murine (one DBA/1J and one DBA1J &#215; C3H F1) synovial fibroblast cell lines were used to test AAV transduction <it>in vitro</it>. The cell lines (2 &#215; 10<sup>5</sup> cells) were infected with 10<sup>4</sup> particles/cell of a murine IL-10-encoding vector (AAV-mIL-10) alone or with the addition of a low titer (100 particles/cell) of an E1-, E3-deleted recombinant adenovirus to provide E4orf6 activity to enhance second-strand synthesis. The supernatants were harvested from the wells at various time points and assayed for mIL-10 expression by ELISA. Both human synovial cell lines infected with AAV alone demonstrated low-level transgene expression throughout the course of the study. However, by day 10, all human cultures coinfected with adenovirus showed a 16- to 56-fold increase in mIL-10 compared to cultures infected with AAV-mIL10 alone. By day 30, a 31- to 135-fold increase was observed. No such increase was observed in any of the mouse cell lines. To determine the AAV transduction efficiency for synovium <it>in vivo</it>, human RA synovial tissues obtained from patients undergoing joint-replacement surgery were implanted subcutaneously on the backs of NOD.CB17-Prkdc SCID mice. After allowing a 2-week period for engraftment, tissues were injected with 3.4 &#215; 10<sup>11</sup> particles of AAV-luciferase alone or in combination with 1.0 &#215; 10<sup>11</sup> particles of adenovirus. Two weeks following AAV administration, the tissues were homogenized and assayed for expression of luciferase. Only the tissues coinfected with adenovirus had luciferase levels above background. A similar experiment with AAV-LacZ demonstrated X-gal staining only of synovial tissues coinfected with adenovirus. These findings demonstrate a preferential ability of AAV to transduce human, compared to mouse, synovial tissue and suggest that second strand synthesis may be a limiting factor in gene transduction. Further studies to elucidate the mechanisms limiting gene transduction in human synovium may allow optimization of this vector for the treatment of arthritis.</p>
      </sec>
   </bdy>
</art>
